Our News / Press Release
NEW PRODUCT! TFLL Pharma® Research Peptides: Epitalon, MOTS-C, BPC-157, TB-500, GHK-Cu, Ipamorelin, CJC-1295
NEW PRODUCTS!
TFLL Pharma Takes a Major Step:
Research Peptide Production Has Now Started in Belgium
[Belgium, May 27, 2025]
TFLL Pharma has taken its innovative approach in human health and longevity one step further by announcing the start of research peptide production in Belgium. This development represents a strategic milestone, not only strengthening the company’s scientific R&D capacity but also providing the international research community with reliable and high-quality peptide solutions.
Produced Peptides
The peptides produced by TFLL Pharma for research purposes include:
⁕ Epitalon
⁕ MOTS-C
⁕ BPC-157
⁕ TB-500
⁕ GHK-Cu
⁕ Ipamorelin
⁕ CJC-1295
Each of these peptides has attracted significant attention in international scientific circles due to their potential effects in cellular health, regeneration, metabolic balance, and longevity research.
TFLL Pharma’s Vision
In line with its vision “Thinking Future Long Life”, TFLL Pharma continues to be a pioneer not only in the field of food supplements but also in the development of advanced molecules for scientific research. The production facility in Belgium ensures quality standards, traceability, and an R&D-driven structure, positioning TFLL Pharma as a trusted partner on an international level.
Quality and Scientific Approach
TFLL Pharma embraces high purity, GMP compliance, and scientific accuracy in its research peptide production. This enables the company to provide reliable and innovative solutions for the needs of the global research community.
“Peptides are among the most important building blocks in modern science for cellular health and longevity research. At TFLL Pharma, we are excited to combine our expertise in this field with our production infrastructure in Belgium. This investment represents a strong step forward not only for us but also for all researchers seeking the healthy living solutions of the future.”
– Serhan Şimşek, PhD – CEO, TFLL Pharma
For more information about TFLL Pharma, please visit www.tfllpharma.com
TFLL Pharma
Contact: Serhan Şimşek, PhD – CEO
Phone:
+90 216 687 09 53
+32 11 286 900
E-mail: info@tfllpharma.com
Website: www.tfllpharma.com
